Case counts in three sets of documents
Each regulator draws on overlapping trial programmes but reports them in its own way: as cases per 1,000 patient-years, as a percentage of people, or as a frequency class. The US label gives both the number investigators reported and the smaller number confirmed after a blinded review panel, a process called adjudication. [1] Canada reports only adjudicated cases and splits them by type. [4]
| Document and analysis | Trulicity® | Comparison |
|---|---|---|
| US label, registration studies, reported [1] | 12 (3.4 per 1,000 patient-years) | Non-incretin comparators: 3 (2.7 per 1,000) |
| US label, registration studies, adjudicated [1] | 5 (1.4 per 1,000 patient-years) | Non-incretin comparators: 1 (0.88 per 1,000) |
| US and Canada, trial of higher doses, adjudicated [1][4] | 1.5 mg: 1 (0.2%) · 3 mg: 2 (0.3%) · 4.5 mg: 3 (0.5%) | No placebo group |
| Canada, phase 2 and 3, adjudicated (9 patients in all) [4] | 5 of 4,006 (0.1%) | Placebo 1 of 703 (0.1%); sitagliptin 3 of 439 (0.7%) |
| EU summary, phase 2 and 3 registration studies [3] | 0.07% | Placebo 0.14%; comparators 0.19% |
| EU frequency class [3] | Rare (≥1 in 10,000 to <1 in 1,000) | — |
Reading single-figure numbers
All of these rows rest on a handful of people. A rate of 1.4 per 1,000 patient-years means roughly one or two confirmed cases for every thousand people followed for a year, and with 5 cases against 1, a single extra diagnosis on either side would shift the comparison a great deal. [1] Of the nine adjudicated cases in the Canadian pool, six were acute, two chronic and one of unknown type; all six in the higher-dose trial were acute. [4]
The two documents point in different directions on the surface. The US registration pool shows slightly more cases on Trulicity® than on non-incretin medicines, while the EU percentage is lower on dulaglutide than on placebo. [1][3] The groups, denominators and follow-up are not the same, and neither figure proves harm or protection. In the higher-dose trial, cases rose from one to three as the dose went up, but with no placebo group and about 600 people per arm, the label draws no dose conclusion. [1]
Lipase and amylase on a blood test
Trulicity® tends to nudge pancreatic enzymes upwards. In the US label, lipase and/or pancreatic amylase rose on average by 14% to 20% from baseline, against up to 3% on placebo; the EU summary gives 11% to 21%. [1][3] Europe states that, without other signs and symptoms, raised enzymes on their own do not predict acute pancreatitis. Canada adds that repeated enzyme measurements in phase 2 and 3 trials did not predict who would develop it and that their clinical meaning is unknown. [3][4]
The Canadian adverse event table shows how often a raised result was recorded, whatever its cause: pancreatic hyperenzymemia in 3.1% on 0.75 mg and 4.4% on 1.5 mg against 2.8% on placebo over 26 weeks, and 4.2% and 4.8% against 3.2% on all comparators in studies up to 104 weeks. [4] This is a table of events seen during treatment, not of reactions judged to be caused by the medicine. A high lipase result therefore needs to be read alongside how you feel, and that interpretation belongs to the clinician who ordered it.
What larger studies and reports found
A 2017 meta-analysis gathered the long placebo-controlled GLP-1 trials, at least two years long, in which pancreatitis was a predefined event reviewed by independent committees. Three trials qualified, with 9,347 people on a GLP-1 medicine and 9,353 on placebo; there was no increase in acute pancreatitis (Peto odds ratio 0.745, 95% CI 0.47 to 1.17), though the authors said more evidence was needed. [5] The abstract does not name the three trials. A 2025 Mayo Clinic Proceedings review likewise notes that high-quality studies have not yet confirmed a raised risk. [9]
Health-records research points the same way. A 2026 retrospective cohort of matched adults with type 2 diabetes, including dulaglutide users, found no increase in acute pancreatitis with GLP-1 medicines, and among those who did develop it, fewer complicated cases (hazard ratio 0.32). [6] Records studies can be skewed by who gets prescribed what. Voluntary US adverse event reports, by contrast, show more pancreas reports than expected for dulaglutide and three related medicines, but metformin and SGLT2 inhibitors used as comparisons showed the same signal, which suggests reporting habits play a part. Median time to the reported event ranged from about 86 to 136 days. [7]
A 2025 case report describes a 62-year-old woman with diabetic kidney disease who developed acute pancreatitis four months into dulaglutide 1.5 mg. For five days she had upper belly pain spreading to her back, nausea and alternating diarrhoea and constipation; amylase and lipase were raised and imaging confirmed the diagnosis. She recovered fully after the medicine was stopped. [8] It is one patient, and it cannot show how often this happens.
Why it might happen, and what is not known
- What the label supports: acute pancreatitis, including fatal haemorrhagic or necrotising forms, has been observed with GLP-1 receptor agonists, Trulicity® among them, and further cases were reported after approval. The label does not state a mechanism. [1]
- Animal findings, of uncertain meaning: in diabetic rats given dulaglutide, the label describes some pancreatic inflammation at the higher doses, while monkeys treated for a year showed none. [1] The label does not say what this means for people.
- Proposed but unproven: the authors of the 2025 case suggest that GLP-1 medicines may tip pancreatitis in people who are already predisposed; that idea has not been measured. [8]
- General medical knowledge: gallstones are the most common cause of acute pancreatitis, and gallbladder disease is itself a separate Trulicity® warning, so a stone passing into a duct is one route clinicians will look for. [11][1]
Common causes unrelated to Trulicity®
NIDDK lists gallstones, heavy alcohol use, inherited pancreas conditions and some medicines as the most common causes of both acute and chronic pancreatitis; infections, abdominal injury, pancreatic cancer and the ERCP procedure are others, and often no cause is found. [11] MedlinePlus adds very high blood triglycerides, autoimmune problems and certain medicines such as estrogens, corticosteroids, thiazides and azathioprine. [10]
The pain of acute pancreatitis is usually in the upper left or middle belly, becomes constant and more severe, can last for days, may be worse lying flat and can spread to the back. People often look ill, with fever, nausea, vomiting and sweating. [10] Ordinary digestive upset on Trulicity® is common and usually eases; the difference lies in pain that keeps building and does not let up. [3]
If the pain starts, and afterwards
- Stop using Trulicity® and call your healthcare provider straight away if you have severe stomach pain that will not go away, whether or not you vomit; the pain may reach your back. [2]
- Canada asks prescribers to stop Trulicity® and any other suspect medicines, order confirming tests and begin treatment. [4] MedlinePlus explains that care usually means a hospital stay with pain relief and fluids through a vein. [10]
- If pancreatitis is confirmed, Europe and Canada say dulaglutide should not be restarted. [3][4]
- Once eating is allowed again, NIDDK describes a healthy, low-fat plan with small, frequent meals, plenty of fluids, limited caffeine and no alcohol. [12]
- Before starting Trulicity®, tell your provider about any past pancreas problem; Canada says it was not studied in people with past pancreatitis and other diabetes medicines should be considered. [2][4]
Trulicity® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that does not go away, with or without vomiting, sometimes reaching the back | Stop Trulicity® and contact your provider at once; emergency care if you cannot reach them | Emergency | Medication Guide [2]; MedlinePlus [13] |
| Belly pain that worsens, with fever or chills, a fast heartbeat, shortness of breath or yellowing of the skin or eyes | Medical care right away; emergency services (911 / 112) if severe | Emergency | NIDDK [11] |
| Constant, intense abdominal pain that is new, even if you are unsure of the cause | Your provider the same day | Today | MedlinePlus [10] |
| A raised lipase or amylase result with no symptoms | The clinician who ordered the test | At your next appointment | EU summary [3]; Canadian monograph [4] |
| Past pancreatitis or other pancreas problems, before starting Trulicity® | Your prescriber | At your next appointment | Medication Guide [2]; Canadian monograph [4] |
